- Indication: Psoriatic Arthritis
- Enrollment Status: Enrollment Open
- Protocol: PA0016 “Be Bold”
- Drug: Zasocitinib
- Sponsor: Takeda
- Description: A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)
